The efficacy of tyrosine kinase inhibitor dasatinib on colonic mucosal damage in murine model of colitis

dc.authoridCan, Hatice/0000-0002-6054-9244
dc.authoridKARACA, Turan/0000-0002-2500-7781;
dc.authorwosidCan, Hatice/ABI-7678-2020
dc.authorwosidKurt, Mevlut/Q-2093-2015
dc.authorwosidKARACA, Turan/ABD-6669-2020
dc.authorwosidkaraboga, ihsan/AAZ-9840-2020
dc.authorwosidCAN, GÜRAY/AAA-3274-2020
dc.authorwosiddemirtaş, selim/JED-6784-2023
dc.contributor.authorCan, Guray
dc.contributor.authorAyvaz, Suleyrnan
dc.contributor.authorCan, Hatice
dc.contributor.authorKaraboga, Ihsan
dc.contributor.authorDemirtas, Selim
dc.contributor.authorAksit, Hasan
dc.contributor.authorYilmaz, Bulent
dc.date.accessioned2024-06-12T11:19:11Z
dc.date.available2024-06-12T11:19:11Z
dc.date.issued2016
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground and objective: Ulcerative colitis is an inflammatory condition of the colon in the gastrointestinal system. Currently, the most potent medications used for ulcerative colitis produce no response in 20-30% of cases. There is a need for more efficient and reliable medications. Tyrosine kinase inhibitors have shown efficacy in some inflammatory diseases. Although dasatinib, a tyrosine kinase inhibitor, suppresses proinflammatory cytokines in colonic tissue, there are a few cases of hemorrhagic colitis with dasatinib. There is no study investigating the effect of dasatinib on experimental colitis. We aimed to investigate the effect of dasatinib in a colitis model induced with acetic acid in our study. Methods: In the study, 24 male Sprague-Dawley rats randomly distributed into 4 groups of 6 rats each as control, dasatinib, colitis and dasatinib + colitis groups. For colitis induction, 4% acetic acid was used. Sacrificing of the rats was performed on the seventh day. Disease activity, morphologic and histological injury, superoxide dismutase, myeloperoxidase and malondialdehyde activity, TNF alpha and CD3 expression were assessed in colonic tissue. Results: Apart from malondialdehyde, significant difference in all parameters between the control and colitis groups was determined. Difference between the colitis and colitis + dasatinib groups was not significant in only weight loss and biochemical parameters. Though dasatinib does not fully resolve the changes in colitis, there was significant regression. Conclusions: Dasatinib decreased the inflammation in a rodent model of colitis. It may be provide this effect by the suppression of TNF alpha. Dasatinib may be one of the treatment options for ulcerative colitis. (C) 2016 Elsevier Masson SAS. All rights reserved.en_US
dc.identifier.doi10.1016/j.clinre.2015.12.006
dc.identifier.endpage516en_US
dc.identifier.issn2210-7401
dc.identifier.issn2210-741X
dc.identifier.issue4en_US
dc.identifier.pmid26823039en_US
dc.identifier.scopus2-s2.0-84957831585en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage504en_US
dc.identifier.urihttps://doi.org/10.1016/j.clinre.2015.12.006
dc.identifier.urihttps://hdl.handle.net/20.500.14551/25093
dc.identifier.volume40en_US
dc.identifier.wosWOS:000388875200024en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Masson, Corporation Officeen_US
dc.relation.ispartofClinics And Research In Hepatology And Gastroenterologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectInflammatory-Bowel-Diseaseen_US
dc.subjectChronic Myeloid-Leukemiaen_US
dc.subjectDextran Sulfate Sodiumen_US
dc.subjectTumor-Necrosis-Factoren_US
dc.subjectUlcerative-Colitisen_US
dc.subjectCrohns-Diseaseen_US
dc.subjectRat Modelen_US
dc.subjectPatienten_US
dc.subjectRemissionen_US
dc.subjectMoleculeen_US
dc.titleThe efficacy of tyrosine kinase inhibitor dasatinib on colonic mucosal damage in murine model of colitisen_US
dc.typeArticleen_US

Dosyalar